Longitudinal association of dietary spermidine with hepatic function indexes and cardiometabolic traits in older adults with metabolic syndrome.

Den longitudinella analysen använde data från baslinjen och efter ett år för 2 664 deltagare i PREDIMED-Plus som var äldre, hade övervikt eller fetma och metabolt syndrom. Intaget av spermidin från kosten bedömdes med ett semikvantitativt kostfrekvensformulär i stället för att deltagarna tilldelades ett tillskott med spermidin. The investigators grouped people into three patterns of intake change across baseline, six months and one year, then used linear mixed-effects models to examine associations with hepatic and cardiometabolic markers. The pattern with the highest baseline intake and a further increase over one year was associated with a mean fatty-liver-index reduction of 8.97 points (95% CI -9.96 to -7.97). The supplied abstract truncates immediately after this result, so it does not provide the other effect estimates or p-values. Its conclusion says that increased dietary spermidine intake was associated with improved hepatic-function indices and cardiometabolic traits. Association is the operative word. Dietary reporting, clustering and observational modelling cannot establish that spermidine itself caused the changes. This is not a randomised supplement trial and does not test a longevity outcome. It concerns a metabolic-syndrome population over one year, so its relevance to healthy people is limited.

A one-year increase in dietary spermidine intake was associated with improvements in hepatic-function indices and cardiometabolic traits in older adults with metabolic syndrome.